高血壓 高尿酸 慢性腎病 胰島素 https://2019medicinenote.blogspot.com/2019/12/blog-post_57.html . 糖尿病相關筆記~目錄 https://2019medicinenote.blogspot.com/2020/01/blog-post_4.html

2020年12月23日 星期三

Famvir 抗濾兒膜衣錠250公絲- 帶狀皰疹特效藥.



BASIC PHARMACOKINETICS

生體可用率 77%, 經肝臟轉換成 penciclovir, 血漿半衰期 2.1~2.7 小時, 食物不影響吸收率(空腹或飯後服用都可以) 
Famciclovir is well absorbed, featuring an oral bioavailability of 77 percent [7]. Prompt first-pass metabolism in the intestine and liver results in conversion to penciclovir. A 500 mg dose of famciclovir yields peak penciclovir levels of 2.7 to 4 mg/L, with a plasma half-life of 2.1 to 2.7 hours. Food has no clinically important effect upon these levels [2].

感染單純皰疹病毒 herpes simplex 的細胞, 細胞內 penciclovir 半衰期10-20 小時, 感染帶狀皰疹病毒 varicella zoster virus 的細胞內半衰期 7-14 小時,相較於半衰期僅不到一小時的 acyclovir, 服用 famvir 一天三次即可. 
A key feature of penciclovir is a prolonged intracellular half-life of penciclovir triphosphate: 10 to 20 hours in herpes simplex virus-infected cells, and 7 to 14 hours in varicella zoster virus-infected cells. In comparison, the intracellular half-life of acyclovir triphosphate is one hour or less [2]. As a result, famciclovir requires less frequent dosing.

排出主藥經過腎臟, 因此腎功能不良 (CCR<60) 需減量 ., 血液透析可移除 penciclovir
慢性穩定性肝病不需減量. 但目前缺乏失償性肝功能不良的研究. 
Excretion is primarily renal, and dose reduction is recommended in patients with impaired renal function (creatinine clearance under 60 mL/min) [1,2]. Penciclovir is removed by hemodialysis [1]. Well-compensated chronic liver disease does not require dose modification, but pharmacokinetic studies in patients with poorly compensated hepatic insufficiency have not been performed [1].

2020年12月21日 星期一

野外與登山醫學---預防高海拔疾病服用acetazolamide 丹木斯需要吃幾天?

2023-10-16 17:17
五天前 WMS 發表 2024 指引更新, 建議跟之前一樣. 
如果遵照指引的每天海拔上升不超過 500 公尺. 且每上升 1000 公尺休息一天, 在抵達最高海拔繼續吃兩天即可, 若上升速率超過建議, 則吃 2-4 天, 如果海拔開始下降就可以停用預防性藥物
但指引中有提到. 如果在海拔5000公尺以上, 預防性用藥可以增加劑量. 改為每次一顆 250mg. 每天兩次. 
註: 以上建議來自專家共識會議. 並無醫療研究數據支持這種策略
  

下面是舊的
1. 到達最高海拔之後, 如果開始下降當天可停用
2. 到達最高海拔之後, 如果持續停留在原地, 可以吃 2-4 天。

如果上升速率沒有超過建議速率, 服用兩天無症狀可考慮停用(WMS建議)
如果上升速率超過建議速率, 服用 2-4 天無症狀可考慮停用(WMS建議)根據風險等級不同, 考慮是否預防性服用丹木斯預防AMS/HACE

Wilderness Medical Society Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2014 Update


2013 NEJM 建議持續服用三天

2014 WMS及 2019WMS 指引建議持續服用 2-4 天.



2020年12月15日 星期二

學童罹患腸病毒感染應該請假多久?

疾病管制署回覆有關孩童腸病毒請假時間如下:

針對轉知「最近兒科醫師有時會被要求開診斷書證明罹患腸病毒感染的兒童可以回幼兒園,這造成兒科醫師的困擾,中央應該已有統一隔離天數的規定。醫師無從判斷病患身上是否還有病毒,是否還有傳染性,疾管署是否有辦法減少這類困擾?」一事,經本署研議後,說明如下:

1. 目前幼童罹患腸病毒之請假規定建議,列於本署2013年2月修訂之「小學、幼兒園及托育機構教托育人員腸病毒防治手冊」及2013年7月修訂之「腸病毒防治工作指引」內文的「教(托)育機構停止上課及兒童請假建議」。

2. 為使建議明確化,除能達到降低傳播風險的目的,且利教托育機構落實辦理,並減少醫師判定上的困擾,前項手冊第13頁及指引第30頁所提「凡經臨床診斷為(疑似)腸病毒感染之幼(學)童,原則上建議其請假一至兩星期(以發病日起算),惟實際請假時間長短,可依醫師指示彈性調整。」乙節,擬修正為「凡經臨床診斷為(疑似)腸病毒感染之幼(學)童,原則上建議以發病日起算,請假一週為原則。」,並增列「腸病毒症狀緩解後,雖然口鼻分泌物中的病毒已較發病時大幅減少,惟仍可經由糞便排放病毒,所以病童返校上課後,仍須注意其個人衛生習慣,避免將病毒傳染給其他幼(學)童。」等文字,提醒教(托)育機構注意,降低傳染風險。

3. 該手冊及指引中對教(托)育機構停課之相關規定,則維持原建議「依據中央公告之強制停課規定(如有),或教(托)育機構所在縣市之停(復)課決策機制,決定該班級是否停課與停課天數。停課天數以一至兩星期為原則。」,保留縣市與機構實施停復課作業之彈性空間。
另外, 教育部國民及學前教育署(以下簡稱國教署)網站也建議, 各縣市政府(教育局、處)依照衛生福利部所制訂之「小學、幼兒園及托育機構教托育人員腸病毒防治手冊」「教托育機構兒童請假及停課建議」制訂停課及通報標準,為落實腸病毒防治,請學校確實依據各縣市政府訂定之停課規定辦理。



2020年11月16日 星期一

腎衰竭貧血施打EPO

傳統的 ESAs 半衰期較短 ( 第一代 : Epoetin alfa and beta: 7~9 hours, 第二代: Darbepoietin alfa: 25 hours),需要增加施打頻率來彌補 ( 如一週三次 ) 。 Continuous erythropoietin receptor activator (CERA)為第三代 ESA,其半衰期較傳統 ESAs 更長(130 hours),故只需 2~4 週施打一次即可。
Roche 藥廠於 2008 年 1 月取得美國 FDA 核准其CERA 製 劑 Methoxy polyethylene glycolepoetin β(Mircera®)用於治療慢性腎病所導致的貧血,包括已在進行透析的患者。

2020年10月29日 星期四

林記賢醫師筆記 vertigo 網路教學資源整理

網路上的Vertigo教學大師: Peter Johns (文長慎入)
兩個月前幫急診住院醫師上課,主題是dizziness。在網路上尋找教學資源時,發現了一位vertigo教學大師:加拿大的急診醫師Peter Johns。他的Youtube頻道把很多複雜的vertigo知識,講得淺顯易懂,看完他的頻道之後,對於vertigo的認識與診斷功力會大增。彭啟峻醫師在台灣急診醫學通訊的文章「在急診診斷與處理BPPV,Youtube自學指引」也有提到他。
https://www.youtube.com/c/PeterJohns/videos
https://twitter.com/PeterJohns84
頻道裡有很多影片,以下是我建議的觀看次序和心得分享
Vertigo myth: Central vs peripheral tables help you make the diagnosis in vertigo
https://www.youtube.com/watch?v=0FL377pUIlA
以前書上都有central vs peripheral的表格,但怎樣都不好用,有什麼問題呢?原來peripheral裡面有兩個非常不一樣的東西:BPPV與vestibular neuritis。影片中說明了舊的教科書表格問題在哪,並建議用新的流程圖來優先找出vertigo的三個診斷:中風、BPPV、前庭神經炎(the big 3)。那個流程圖是Peter Johns發表在CMAJ上的,同時也收錄在新版Tintinalli 9th的Vertigo章節。(Peter成為該章節作者之一,而章節裡也真的把central vs peripheral表格拿掉了)
Big 3 of vertigo
https://www.youtube.com/watch?v=MwbqJvMDonU
Peter進一步說明如何在急診抓出big 3,但是診斷並不止big 3。還有大家都有聽過的HINTS plus exam,應該用在什麼樣的人?不應該用在什麼樣的人?
Possible Neurologic Findings in Cerebellar brainstem stroke
https://www.youtube.com/watch?v=bX34DQnkfRU
說明 big 3流程圖一開始的神經學評估。
HINTS plus exam
https://www.youtube.com/watch?v=84waYROlI4U
關於HINTS plus exam更進一步的詳細解說,還有操作時要注意動作的細節。
Clinical diagnosis of vestibular neuritis using the HINTS plus exam
https://www.youtube.com/watch?v=dy6FsKS0LHY
在急診用HINTS plus診斷前庭神經炎。看完之後我發現原來以前有很多暈眩的病人都有可能是前庭神經炎啊,只是我沒有給他們診斷而已。
Clinical diagnosis and treatment of BPPV using the Dix-Hallpike test and Epley maneuver
https://www.youtube.com/watch?v=kvVnEsGVLUY
常見的後半規管BPPV診斷術Dix-Hallpike test(DHT)及Epley maneuver復位術。我們店裡有時太忙,太少幫病人做復位術了,給大家復習一下怎麼確診BPPV?怎麼復位?要是有點時間,對典型DHT出現up-beating/torsional nystagmus的病人,復位術做完症狀就好很多,可以減少急診暫留時間。
Horizontal Canal BPPV
https://www.youtube.com/watch?v=VRjRTnIw9YE
若病史像BPPV,但DHT做出來沒有反應,或是呈不典型的水平眼震,那就改做supine roll test (SRT)來診斷,並用Gofoni maneuver復位術。HC-BPPV的定位方式較複雜,Gofoni從哪邊做?轉哪邊?Peter提供了一個有趣好記的口訣。****這個Gufoni maneuver我非常推薦,治療效果非常好,過程病人也不太會不舒服,而且hc-BPPV感覺沒有很少見,學會這個復位術非常值得。
Anterior Canal BPPV
https://www.youtube.com/watch?v=2TAYDp3vVTU
很罕見,做DHT會出現向下眼震。但是這個finding也有可能是 central mimics of BPPV (CPPV),我記得有個ENT醫師說過他有個病人DHT向下眼震,他想說抓到AC-BPPV了!結果復位治療完沒比較好,後來診斷是小腦出血…
Vertigo myth: "All vertical nystagmus is central in origin"
https://www.youtube.com/watch?v=V4C_BRNf1EI
澄清迷思:所有的垂直眼震都是central嗎?其實pc-BPPV做DHT就會出現垂直眼震啊XD,後面譙了central vs peripheral表格。
Vestibular Migraine- A very common but rarely diagnosed cause of vertigo
https://www.youtube.com/watch?v=XPIyXiv0UKg
暈眩的病人不在big 3診斷裡,還有什麼常見診斷呢?vestibular migraine
What about posterior circulation TIA's?
https://www.youtube.com/watch?v=9_o0E1IzsCM
後循環TIA在文獻裡講的很常見,真的嗎?Peter不這麼認為,並提供他認為那些文獻的問題:詢問後循環中風的病人,來診之前的一陣子,有沒有isolated vertigo?這樣回溯式的問法,可能其實病人當時有其他的症狀但忘記了,或是病人當時有neuro sign但沒有被做NE。影片最後也有提到遇到isolated transient vertigo,他的建議為何。我覺得很符合台灣急診的現況,病人暫時性的isolated vertigo現在又無症狀了,無法說服神內當成TIA收住院的。但是病人剛才vertigo時同時有diplopia或其他神經學症狀,那對神內就有說服力多了。

ps. 裡面他有所批評的文章作者Dr. Edlow,也是一位vertiog教學達人
他的代表文章在這裡https://pubmed.ncbi.nlm.nih.gov/30743290/
他的教學影片在這裡https://www.acep.org/....../lecture---why-39what-do....../
我寫信問了Peter Johons關於這篇文章的看法 “STANDING algorithm”
https://pubmed.ncbi.nlm.nih.gov/29163350/
他覺得這個診斷流程很不錯,但是他們少做了test of skew,而且他們看眼震是用Frenzel lens,跟一般急診直接看,不太一樣。我覺得這篇給我們一點信心,那就是頭暈但可以自己走得穩的病人,放他回去,誤診率只有0.7%而已。
總結:網路上的vertigo教學資源雖然多,但是我最推薦的YT頻道還是Peter Johns,因為他講得最清楚,而且加拿大的醫療糾紛不像美國那麼多,跟台灣比較像(吧)。
知名急診blog Life in the Fast Lane也有推薦他的方法
https://litfl.com/vertigo-the-big-3/
知名急診教學網站EM cases podcast終於找他來講一下vertigo (32:41)
https://emergencymedicinecases.com/em-quick-hits-23....../
最近有一偏SR/META說,沒有證據說急診醫師自己做HINTS可以準確排除中風。
https://pubmed.ncbi.nlm.nih.gov/32167642/
但是坦白說這篇文章的META收錄部分,有關「急診醫師做HINTS」的文章真的不多。我想是否急診醫師自己根本就很少在做HINTS,才會沒有足夠的證據。
為了這個話題,Peter也在Twitter上跟人筆戰了XD
https://twitter.com/MKleinMD/status/1321088549043789825
蠻多美國的急診醫師對於vertigo持續的病人,還是建議做MRI,可能醫療糾紛的壓力比加拿大高很多。
我的看法:盡力把明顯中風和明顯BPPV抓出來先,當遇到acute vestibular syndrome時,要做HINTS plus嗎?還是要會診神內?其實都合理。先問問自己對診斷有沒有信心,還有考量當地的醫療糾紛嚴重程度。最近兩個月診斷了一些前庭神經炎,因為經驗還不是很充足,蠻多病人我有會診神內,雖然不見得每個神內醫師都知道HINTS plus,但有他們來看過病人,確實比較放心。大部分都會建議留觀給藥supportive care,如果症狀還很持續,就做brain MRI,而這些MRI都是negative。(MRI太早做容易miss小中風,所以觀察完再做很合理)

2020年10月6日 星期二

TG 三酸甘油脂 triglyceride

from uptodate
中度高血脂 150-885 mg/dL
嚴重高血脂 ≥885 mg/dL

SUMMARY AND RECOMMENDATIONS
●This topic refers to the range of fasting triglyceride (TG) levels from 150 to 885 mg/dL (1.7 to 10 mmol/L) as moderate hypertriglyceridemia and ≥885 mg/dL as "severe" hypertriglyceridemia. (See 'Definition' above.)

●Elevated TG levels are independently associated with atherosclerotic cardiovascular disease (ASCVD) risk, particularly coronary heart disease risk. However, causality has not been established. (See 'Association with ASCVD' above.)

三酸甘油脂過高, 應先嘗試非藥物治療, 改善生活型態, 減重, 有氧運動, 避免醣類, 注意是否有其他會造成TG上升的藥物. 如果有糖尿病, 應嚴格控制血糖, 作為第一線治療. 
其他心血管動脈粥狀硬化的危險因子也要重視, 例如高血壓, 抽菸. 
●All patients with hypertriglyceridemia should participate in nonpharmacologic lifestyle interventions such as weight loss in obese patients, aerobic exercise, and avoidance of concentrated sugars and medications that raise serum TG levels. Excellent glycemic control in patients with diabetes should be first-line therapy. Other risk factors for ASCVD, such as hypertension and smoking, should also be addressed. (See 'Management' above.)

如果TG過高同時合併LDL過高, 應考慮使用 statin 治療
●All patients with hypertriglyceridemia should have an assessment of their low-density lipoprotein cholesterol level. If the patient is not at goal, statin therapy should be considered. (See 'Triglyceride levels between 150 and 885 mg/dL' above.)

若經過非藥物治療, TG仍然超過 885, 建議給予 fibrate 治療
●For patients with TG levels persistently >885 mg/dL (10 mmol/L) after nonpharmacologic interventions, we suggest starting drug therapy to lower the risk of pancreatitis (Grade 2C). We start with a fibrate. (See 'Triglyceride levels above 885 mg/dL' above.).

以經服用statin的患者, 如果TG介於 150-885 之間, 應考慮給予第二種降血脂藥物. 通常選擇每天吃 四公克 魚油  Vascepa 0.5g capsules icosapent ethyl
●For patients with TG levels between 150 mg/dL (1.7 mmol/L) and 885 mg/dL (10 mmol/L) taking statin therapy, we suggest adding a second lipid-lowering drug, for cardiovascular disease events (Grade 2C). (See 'Triglyceride levels between 150 and 885 mg/dL' above.)

We usually start with icosapent ethyl (fish oil) 4 g daily.

●For patients with hypertriglyceridemia not clearly associated with a secondary cause, we screen family members with a fasting TG level. (See 'Screening' above.)

2020年10月4日 星期日

流感疫苗的不良反應及112 年度流感疫苗接種計畫常見問答 Q&A

2023-10-02 新增
112 年度流感疫苗接種計畫常見問答 Q&A





疾管署的公告裡面提到, 48小時內有 1-2% 的人出現發燒

流感疫苗是死病毒製成的不活化疫苗, 因此不會因注射疫苗感染流感

接種後可能會有注射部位疼痛、紅腫,少數的人會有全身性的輕微反應,如發燒、頭痛、肌肉酸痛、噁心、皮膚搔癢、蕁麻疹或紅疹等,一般會在發生後1至2天內自然恢復。(沒註明機率)

WHO 的訊息有提到幾種副作用/不良反應的機率. 不過有些是比較久遠的研究



























. .




台灣水痘疫苗

民國85年, 台北研究, 十歲兒童的水痘抗體陽性比例 84%

民國86年(1997)核准水痘疫苗進口

台北市 1997 免費施打水痘疫苗

台中縣 1998 免費施打水痘疫苗

2004 衛生署為全國滿一歲以上兒童免費施打水痘疫苗


2020年9月27日 星期日

魚油 OMACOR EPA

自費的藥品級魚油, 健保沒有給附

OMACOR 1000MG 一顆約 60 元, 成分是DHA/EPA
VASCEPA 魚油成分處方藥物, 可輔助statin, 用於降低 TG 三酸甘油酯 


子公司科進製藥國產新成份新藥脂妙清軟膠囊1000毫克﹝Omacor Soft Capsules 1000mg)於2016年4月12日獲得台灣衛生福利部食品藥物管理署(TFDA)通過查驗登記核發藥品許可證。許可證字號:衛部藥製字第059019號,適應症為高三酸甘油酯(血)症,預計將於7月在台灣上市。

純 EPA 一顆約 50 元

臨床研究目前發現, 80%以上EPA/DHA濃度才有降低高血脂/三酸甘油脂的效果

預防心血管疾病, EPA 需要吃 1.8~4 gm 才有效果. 
改善憂鬱症, EPA一天一顆, 兩周見效, 如果兩周效果不佳, 可加量再吃兩周, 如果再沒效果, 表示可能屬於無法以EPA改善的類型, 目前認為體內 omega 3. 缺乏引起的憂鬱症, 補充 EPA 會有效果. 但憂鬱症還有其他成因, 並不只限缺乏 omega 3 

EPA生體可用率與濃度有關, 濃度低, 總劑量相同, 與高濃度的作比較, 吸收率較差, 所以並不是低濃度的多吃幾顆就可以達到高濃度的效果.

陳信潔藥師 一次簡單搞懂藥品級魚油脂妙清Omacor ®
https://www.youtube.com/watch?time_continue=7&v=IZM22gfTt2A&feature=emb_logo



2020年9月24日 星期四

運動處方 EIM 範例

70 歲男性,身體健康,退休後想維持體能,預防心血管疾病。

休息時心跳為 70 下, 血壓 130/80 mm-Hg。 

運動處方 運動的型態:以在公園或學校操場等平地步行為主 

運動強度:中等,每分 100 ~ 120 次心跳,約每秒踏 2 至 3 步的速度

目標心跳=0.7 × (220-70)=105 

考慮心跳變異性,故加、減 10%:105±(105 ×10%)≅ 100 ~ 120 

運動時間: 

下肢伸展運動 5 分鐘 

目標心跳運動時間 20 分鐘 

緩和運動時間 5 分鐘 

運動頻率:一星期三次 

運動進展:一個月後,觀察反應再進行決定。




運動處方 名詞定義

%HRR:保留心跳率 最大心跳率:220-年齡 (易有誤差)
最大心跳率算法:206.9-(0.67×年齡)
%HRR=(最大心跳率-安靜心跳率)×運動強度%+安靜心跳率 resting heart rate

有氧運動強度
高強度運動 60%~90% HRR 
中等強度運動 40%~59%HRR 
低強度運動 20~39 %HRR

Physical activity (PA) 日常身體活動, 骨骼肌收縮, 會增加能量支出
Physical activity (PA): body movement that is produced by the contraction of skeletal muscles and that increases energy expenditure 

最大心跳速率與攝氧量關係
70-85%的 HRmax 約等於 55-75%的最大攝氧量

攝氧量(Oxygen uptake):
攝氧量等於心輸出 量(Cardiac output = heart rate × stroke volume) 乘以動、靜脈血氧濃度差 (A-VO2diff)
通常 以 L/min 或 ml/kg/min 或 MET 來表示(1 個 MET 相當於消耗 3.5 ml/kg/min 的氧氣)
在某種程度上它反映了運動的強度(Exercise intensity)。
而最大攝氧量為代表最大運動能 力(Maximal exercise capacity)的最佳指標。
由前述公式得知在一般情形下,一個人的心跳 應可反應攝氧量,故也間接地代表運動強度。

依據 1998 年美國 運動醫學會建議分成分為軽、中、重、極重四 種強度。
以攝氧量處方
低於 40%最大攝氧量,代表輕度運動;
40-50%最大攝氧量,代 表中度運動;
50-85%最大攝氧量,代表重度運 動;
85%以上最大攝氧量,代表極重度運動。
心 跳可反映運動強度,
低於 55%最大心跳,代表輕度運動;
55-65%最大心跳,代表中度運動; 
65-90%之最大心跳,代表重度運動;
90%以上 之最大心跳,代表極重度運動。

若有運動測試 的結果,可以攝氧量為處方,單位為 L/min,數值再除以(3.5×體重),則為 MET

2020年8月27日 星期四

過敏性休克使用腎上腺素每 5-15 分鐘給予一次肌肉注射

2005 ACLS 建議. 肌肉注射epinephrine 5-15 分鐘給一次.
Epinephrine
–Absorption and subsequent achievement of maximum plasma concentration after subcutaneous administration is slower and may be significantly delayed with shock.10,11 Thus, intramuscular (IM) administration is favored.
Administer epinephrine by IM injection early to all patients with signs of a systemic reaction, especially hypotension, airway swelling, or definite difficulty breathing.
Use an IM dose of 0.3 to 0.5 mg (1:1000) repeated every 15 to 20 minutes if there is no clinical improvement.
–Administer IV epinephrine if anaphylaxis appears to be severe with immediate life-threatening manifestations.
Use epinephrine (1:10 000) 0.1 mg IV slowly over 5 minutes. Epinephrine may be diluted to a 1:10 000 solution before infusion.
An IV infusion at rates of 1 to 4 μg/min may prevent the need to repeat epinephrine injections frequently.
–Close monitoring is critical because fatal overdose of epinephrine has been reported.3,14
–Patients who are taking β-blockers have increased incidence and severity of anaphylaxis and can develop a paradoxical response to epinephrine.15 Consider glucagon as well as ipratropium for these patients (see below).
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.105.166568

2015指引. 使用 2010 ACLS建議, 沒有新的變動
The recommended dose is 0.2 to 0.5 mg (1:1000) IM to be repeated every 5 to 15 minutes in the absence of clinical improvement (Class I, LOE C).
https://eccguidelines.heart.org/tables/2015-guidelines-update-part-10-recommendations/

2020年8月13日 星期四

皮膚理學檢查描述 signs of skin lesion

primary skin lesion. 

1.斑(Macule):皮膚顏色改變,界限分明,未突起之平面,通常小於1公分,如雀斑、瘀斑。
2.斑塊(Patch):如上述之病變,但大於1公分之病變,如白斑病(Vitiligo)。
3.丘疹(Papule):平坦突起,可觸摸得到之病變,但皮表未破損,通常小於0.5公分,如痣。
4.丘斑(Plaque):比丘疹大之平坦突起,常由丘疹合併而成。
5.結節(Nodule):突起之硬結,0.5-2公分。
6.腫瘤(Tumor):突起之硬結大於2公分。
7.風疹塊(Wheal):不規則之平坦突起,如蚊叮後之突起、蕁麻疹之突起。
8.小水泡(Vesicle):小於0.5-2公分的皮膚突起,其界限分明且包含漿液,如單純性泡疹(Herpes Simplex)
9.水泡(Bulla):大於2公分以上之皮膚突起,界限分明且包含漿液,如二度燒傷時的水泡。
10.膿泡(Pustule):包含膿汁的皮膚突起,如粉刺(Acne)、膿泡疹(Impetigo)。

secondary skin lesion 
1.糜爛(Erosion):表皮缺失之潮濕表面,但無出血現象,癒合後無疤痕
2.潰瘍(Ulcer):皮膚表面及較深組織缺失,會出血,癒合後結疤。
3.裂隙(Fissure):皮膚上線狀裂縫,面小但是可能深。


1.痂皮(Crust):血清、膿汁和血液的乾燥物。
2.鱗屑(Crust):表皮乾燥脫落的薄片。如頭皮屑、牛皮癬。
3.苔癬化(Lichenification):皮膚變厚、變粗、皮膚上的紋理十分明顯,甘變異性皮膚炎。
4.萎縮(Atrophy):皮膚變薄,紋理不明、皮表顯得發亮。如動脈供給不良之皮膚。
5.疤痕(Scar):癒傷後修補傷口的纖維組織,常比正常皮膚色澤淺,且沒有紋理。
6.疤痕疣(Keloid):增生之疤痕組織,常凸起皮表且呈樹突狀分枝。
Pathology on line/ Skin nontumor > Common terms
Definition / general
Acantholysis: loss of intercellular connections (desmosomes) between keratinocytes; occurs in pemphigus vulgaris and related disorders; causes change in cell shape from polygonal to round
Acanthosis: thickening of epidermis (squamous layer); rete ridges usually extend deeper into dermis
Atrophy: thinning of epidermis, associated with age or disease
Basophilic degeneration: age and sunlight related changes of collagen and elastic fibers
Blister 水泡: vesicle or bullae
Bullae 大水泡/大皰 : fluid filled area > 5 mm; either intraepidermal or subepidermal; intraepidermal bullae are due to spongiosis or acantholysis; subepidermal bullae are due to extensive papillary dermal edema
Calcinosis 鈣沉積: deposit of calcium
Colloid bodies膠體 : also called Civatte bodies; apoptotic keratinocytes, are oval / round, immediately above or below epidermal basement membrane
Comedo 毛囊漏斗擴張 : hair follicle infundibulum is dilated and plugged with keratin and lipids
Cyst: encapsulated cavity or sac lined by true epithelium
Dyskeratosis 角化異常 : abnormal, premature keratinization of keratinocytes below granular cell layer; often have brightly eosinophilic cytoplasm
Epidermolysis 表皮分解 : alteration of granular layer with perinuclear clear spaces, swollen and irregular keratohyalin granules, increased thickness of granular layer; different from acantholysis
Epidermotropism: atypical lymphocytes present in epidermis (seen in cutaneous T cell lymphoma)
Erosion: discontinuity of skin causing partial loss of epidermis (compare to ulceration)
Excoriation: deep linear scratch, often self-induced
Exocytosis: normal appearing lymphocytes in epidermis (spongiotic dermatitis)
Horn: conical mass of cornifed cells
Hydropic (liquefactive) degeneration: basal cells become vacuolated, separated and disorganized
Hyperkeratosis: thickened cornified layer, often with prominent granular layer; keratin may be abnormal; either orthokeratotic (hyperkeratosis is exaggeration of normal pattern of keratinization with no nuclei in cornified layer) or parakeratotic (hyperkeratosis has retained nuclei in cornified layer)
Lentiginous: linear pattern of melanocytic proliferation within epidermal basal cell layer
Leukocytoclasis: karyorrhexis and destruction of neutrophils; occurs with neutrophilic vasculitis (also called leukocytoclastic vasculitis)
Lichenification: thick, rough skin with prominent skin markings usually due to repeated rubbing
Lichenoid interface change: destruction of basal keratinocytes, causing remodeling of basement membrane zone; also bandlike lymphocytic infiltrate
Macule: circumscribed flat colored area of any size
Nodule: solid, deeply extending lesion > 5 mm
Oncholysis: loss of integrity of nail substance
Papillomatosis: outward overgrowth of epidermis with elongation of dermal papillae
Papule: elevated and solid area, 5 mm or less
Parakeratosis: cells of cornified layer retain their nuclei, often less prominent or absent granular layer; normal for mucous membranes
Patch: flat discoloration > 5 mm
Papule: solid elevated lesion < 5 mm
Plaque: elevated flat topped area, usually > 5 mm
Poikiloderma: combination of atrophy, telangiectasia and pigmentary changes
Purpura: extravasation of red blood cells into the skin or mucous membranes
Pustule: intraepidermal or subepidermal vesicle or bullae filled with neutrophils
Scale: dry, horny, platelike excrescence usually due to imperfect cornification
Scale crust: parakeratotic debris, degenerating inflammatory cells and tissue exudate on surface of epidermis
Sinus: tract connecting cavities to each other or to the surface
Spongiosis: intraepidermal edema, causing splaying apart of keratinocytes in stratum spinosum (resembling a sponge), vesicles due to shearing of desmosomes
Ulceration: discontinuity of skin causing complete loss of epidermis and possible loss of dermis
Vesicle: fluid filed area, 5 mm or less
Wheal: itchy, transient, elevated area with variable blanching and erythema, due to dermal edema

2020年7月31日 星期五

2014年北醫發表的研究 Stroke: Morbidity, Risk Factors, and Care in Taiwan

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060269/

1986年盛行率, 36歲以上成人, 千分之 16.42
其他研究數據為 千分之 14.27 及 千分之 19.3
男性中風盛行率為 千分之 25.5
女性中風盛行率為 千分之 12.6

Prevalence

Hu et al. reported the stroke prevalence for 8,705 people aged 36 or older was 16.42/1,000 population (95% CI=13.89-19.42/1,000) in 1986. The other studies estimated stroke prevalence of 14.27 per 1,000 in the people aged 35 or older using data from the 1994 National Health Interview Survey (NHIS) and 19.3 per 1,000 people from 2001 NHIS. In males, the stroke prevalence is 25.5 per 1,000 people, almost two-fold higher than the stroke prevalence in females (12.6 per 1,000 people). The level of urbanization, gender, heart disease, hypertension, and diabetes were important contributory factors to the stroke prevalence in Taiwan. The studies of stroke prevalence are summarized in Table 1.

Stroke incidence rising in Taiwan contrary to falls in Western countries

https://www.eurekalert.org/pub_releases/2018-09/esoc-sir092618.php

使用台灣健保資料庫研究, 分析 13 年之間, 台灣人的首次中風發生率

This study examined the incidence of stroke over a 13-year period in Taiwan. For this nationwide cohort study, researchers reviewed the records of all hospitalised patients with a primary diagnosis of stroke between 2001 and 2013 from the Taiwan National Health Insurance Research Database.

共發現 2萬3023 人初次中風, 其中 66.9% 為缺血性中風, 21.1% 是出血性中風, 2.9% 蛛網膜下腔出血, 另有 9.1% 無法歸類

A total of 23,023 first-ever strokes were identified. Of those, 66.9% were ischaemic stroke, 21.1% were intracerebral haemorrhage, 2.9% were subarachnoid haemorrhage, and 9.1% were of undetermined type.


經過年齡調整之後, 缺血性中風機率 110-122/每十萬人每年, 出血性中風機率  30-38 每十萬人每年, 蛛網膜下腔出血機率不變. 

After adjusting for the rising age of the population, the researchers found that the incidence of ischaemic stroke increased from 110 to 122 per 100,000 person-years, intracerebral haemorrhage increased from 30 to 38 per 100,000 person-years, and the rate of subarachnoid haemorrhage was stable.

1992年台北榮總研究 Incidence of Stroke in Taiwan

35歲以上成人, 每年中風發生率, 男性十萬分之 378, 女性十萬分之 280, 平均十萬分之 330
The crude average annual incidence rate of first-ever stroke in inhabitants in Taiwan above age 35 years was 330 per 100,000 (378 per 100,000 for men and 280 per 100,000 for women). The age-adjusted incidence rate was 329 per 100,000 (348 per 100,000 for men and 301 per 100,000 for women) (Table 1).

高血壓與高鹽飲食會增加中風機率
高血壓增加 1.9 倍中風機率
高鹽飲食增加 1.3 倍中風機率
In the present study, age-adjusted risk ratio for hypertension was 3.75. Other significant risk factors of stroke in the current study were consumption of alcohol and salty food (Table 4). After multivariate adjustment for age, sex, and all factors in Table 4, age, hypertension, and salty food remained significant and independent risk factors for stroke, with a risk ratio of 1.9 for hypertension and 1.3 for salty food (/?<0.05).

2020年5月26日 星期二

阻力訓練 Resistance exercise training (RET)

阻力訓練可以增加肌肉量.
*High total energy expenditure leads to increased longevity (JAMA 2006;296:171) *Resistant exercise can increase muscle mass. (J Gerontol: Med Sci 2006; 61A: 78. J Appl Physiol 2001;90:2341)

Trunk Flexion extension.
Hip abduction/adduction

另, 老人的預防失能可以參考韓德生醫師的PPT
https://www.tma.tw/TakeCare2018/files/0819_4.pdf

靜態阻力訓練. 肌肉長度不改變 isometric exercise.




還可以利用家中的環境作阻力訓練, 下面是露天拍賣的商品. 
Foam Door Anchor Resistance Exercise Band Arm Back Muscle Training ...
也可以利用橡皮帶作訓練












老人的肌衰弱測試



.
.
.
.


運動處方 EIM 運動可治療的疾病

1. 關節炎 arthritis
Prevention: possibly through weight control
• Treatment: yes
• Effective modality: AET, RET, aquatic ex
– Low impact
– Adequate volume to achieve healthy weight

Cancer
• Prevention: yes 
• Treatment: yes, for QOL, wasting, lymph edema, psychological function, breast ca survival 
• Effective modality: AET, RET


COPD
• Prevention: no 
• Treatment: yes, for extrapulmonary benefit 
• Effective modality: AET, RET 
– RET is more tolerable in severe dis, complementary effects in combined modality 
– Ex with bronchodilator use 
– Use O2 during ex if needed

Cognitive impairment
• Prevention: yes 
• Treatment: yes 
• Effective modality: AET, RET 
– Mechanism unknown 
–Need supervision in dementia

Hypertension
• Prevention: yes 
• Treatment: yes 
• Effective modality: AET, RET 
– Large change in those reduce weight 
– Small reduction in both SBP & DBP

Osteoporosis
• Prevention: yes 
• Treatment: yes 
• Effective modality: AET, RET, balance training, high-impact ex 
– Weight bearing, high-impact, high-velocity (jump) 
– RET effect is local around contracted muscles 
– Balance training to prevent fall

Peripheral vascular disease 
• Prevention: yes
• Treatment: yes 
• Effective modality: AET, RET 
– Systemic vascular effect 
– Ex volume to the limits of pain tolerance to improve claudication 
– RET is less robust


Benefits of AET in older adult
• Aerobic ex capacity (A): sufficient AE intensity (>60% of pretraining VO2max), freq, and length (>3 d/wk for >16 wk) increase VO2max in healthy middle & old aged adults 
• CV effects (A): >3 mo of mod-intensity AE elicits CV adaptations in healthy middle & old aged adults, at rest & acute dynamic ex 
• Body composition (A/B): mod-intensity AET reduce body fat in obese middle & old aged adults, no effect on FFM 
• Metabolic effect (B): AET can enhance glycemic control, augment postprandial lipids clearance, and utilize fat during submax ex 
• Bone health (B): AET can counteract agerelated decline in BMD in post-menopausal ˖
• Muscle strength can be increased after RET(A)
• Muscle quality is increased after RET(B). similar between older and younger, male and female
• Muscle endurance can be improved by mod- or high-intensity RET, not low-intensity (C). 
• Body composition (B/C): FFM increased. FM decreased with mod- or high-intensity RET
• High-intensity RET improved BMD relative to sedentary control(B)
• Metabolic and endocrine effects (B/C): the evidence is mixed. 

Benefits of balance training in older adult 
• (C): Multimodal ex, including stength and balance ex, and Tai-chi 太極拳 have been shown to be effective in reducing the risk of non-injurious and sometimes injurious falls in populations who are at elevated risk of falling. 

Benefits of stretching and flexibility training in older adult
(D) there is some evidence that flexibility can be increased in the major joints by ROM ex; however, how much and what types of ROM ex are most effective have not been established. 

運動處方
FOTT-Pro
= frequency, intensity, time, type, proression. 
種類
- AET aerobic exercise training: jog, stair climb, brisk walk, bicycle, swim
- Resistance exercise training RET: weight lift, theraband, weight training. 
- Flexibility exercise: stretch
- balance impact exercise: sprinting, single-leg stance
特異性

有氧運動
- 中等強度 for 30-60 min on 5d/wk, 或vigorous-intensity 激烈強度 20-30 min on 3d/wk (1A). 
- 10 point scale (sitting 0, all-out 10)
~ mod: 5/6 , noticeable increase in HR and Breath. 
~ vig: 7/8 , large increase in HR and breath
- Routine light-intensiry ADL or mod-intensity activity < 10 min are not included. 
- Walking, stationary bike, aquatics (NWB no weight bearing). 
- define aerobic intensity by fitness, instead of absolute term (eg, MET). 
~~ 50-85% of O2 uptake reserve
~~5-8/10 of perceived effort 自覺運動強度
~~~ correlated but not linearly
~~A period of supervised exercise may help them learn the desired level of effort 



肌力訓練
Muscle-strengthening activity
• Maintain or increase muscular strength and endurance >2d/wk (IIaA) 
• At least 1 set of 8-10 ex using major m. on 2 or more nonconsecutive days per wk 
• 8-12rep, 1-3set, mod to high intensity 
• 10-point scale (no move:0, max effort:10) – Mod-int: 5/6, High-int: 7/8 – 40-50% 1RM -> 60-80% 1RM 
• Mode: progressive wt training, wt bearing calisthenics, stairs climbing, similar resistance ex
 

Greater amount of activity 
• Additional health benefits & physical fitness in higher levels of AE/RE(IA) 
– If no condition preclude higher amounts of PA 
      • Improve fitness 
      • Improve management of existing dz 
      • Reduce risk of premature chronic condition 
• Higher impact weight bearing activity for skeletal health (IIaB) 
• Higher PA for preventing weight gain (IIaB)


Flexibility activity
• 2 d/wk for >10 min/d to maintain flexibility necessary for regular PA and daily life (IIbB) 
• Major muscle and tendon with 30-60s for a static stretch 
• Stretch to the point of feeling tightness or slight discomfort; static, not ballistic 
• Perform on the day that AE or RE is performed 
• Specific health benefit is unclear 
   – Reduce risk of ex-related inj

Balance exercise
• Balance exercise to reduce risk of falls in community-dwelling older adults (IIaA) 
• Multi-component interventions prevent fall in community elderly 
• Ex, not activity (eg.dancing) is recommended, though PA itself could reduce falls 35-45% 
• 3 times/wk? Preferred types, frequency, and duration are unclear 
• No evidence for LTC and hospital setting

整合預防性及治療性活動
• 對許多疾病而言是相同的
• 骨質酥鬆為例, 預防性運動: 有氧,阻力, 平衡, 柔軟度,
  • 強調負重急高衝力活動, 例如跳躍 
   –Osteoporosis as example: preventive for aerobic, resistance, balance, flexibility. Emphasize wt bearing and high impact activity, like jumping

• At least avoid sedentary behavior, when chronic conditions preclude minimum recommended activity. – Activity limitation: assess the nature of the activity limitation, the capability and preferences of the person. Usually determine the target activity level and details of activity plan mostly in CR/PR centers, or ex classes.

老人照護的一般原則
- 不要給太辛, 太複雜活動, 最好是老人們以前熟悉有興趣的
- 從低強度開始, 隨時保持警覺性, 適時加以調整老人們活動內容及強度
- 提供老人安全舒適的活動空間, 例如照明, 地板防滑, 行進動線, 洗手間設備等. 
- 注意老人服用多種藥物的情況. 








 

2020年5月22日 星期五

野外與登山醫學---高海拔腦水腫 High Altitude Cerebral Edema 2019-12-17 by Jacob D. Jensen; Andrew L. Vincent.

High Altitude Cerebral Edema (HACE)
Jacob D. Jensen; Andrew L. Vincent.
Last Update: December 17, 2019.

Introduction 簡介
高海拔腦水腫 HACE 是高海拔疾病的嚴重潛在致死表現, 特徵是運動失調, 疲憊, 神智改變
HACE 被視為是 AMS 末期表現, 雖然 HACE 在高海拔疾病的發生率不高, 但可能在 24 小時內致死
(並非一定能活 24 小時, 而是 24 小時內若沒有適當診斷治療可能死亡)
(HACE沒有黃金時間, 一但診斷需立即處置)
High Altitude Cerebral Edema (HACE) is a severe and potentially fatal manifestation of high altitude illness and is often characterized by ataxia, fatigue, and altered mental status. HACE is often thought of as an extreme form/end-stage of Acute Mountain Sickness (AMS). Although HACE represents the least common form of altitude illness, it may progress rapidly to coma and death as a result of brain herniation within 24 hours, if not promptly diagnosed and treated.

Etiology 病因
HACE通常在上升到海拔 4000m 以上兩天後發生, 但也可能在較低海拔 2500m 快速發生. 
有一些患者會出現AMS症狀, 但並非全部. 也有些人會同時罹患 HAPE.
單獨發生HACE較罕見, 但即使沒有先出現 HAPE或 AMS, 也不能直接排除 HACE.
HACE generally occurs after 2 days above 4000m but can occur at lower elevations (2500m) and with faster onset. Some, but not all, individuals will suffer from symptoms of AMS such as headache, insomnia, anorexia, nausea prior to transitioning to HACE. Some may also have concomitant High Altitude Pulmonary Edema (HAPE). HACE in isolation is rare, but the absence of concomitant HAPE or symptoms of AMS prior to deterioration does not rule-out the presence of HACE. 

Epidemiology 
HACE在海拔 4000-5000 公尺的盛行率約 0.5-1%, HACE 會影響各年齡層與性別, 但年輕患者的機率較高 (年輕人較高的原因, 例如帶著症狀上升, 或爬升速率較快)

HACE危險因子包括
1. prior history of high altitude illness 先前曾經罹患高海拔疾病
2. lack of acclimatization 缺乏高度適應
3. heavy physical exertion 大量體力活動
4. rapid rate of ascent 快速上升
5. abrupt ascent from lower altitudes. 突然從低海拔爬升至高海拔

Incidence of HACE is 0.5-1% at altitudes of 4000-5000 m. HACE affects those of all ages and genders, though younger males may be at higher risk due to continuation of ascent despite symptoms of AMS and faster rate of ascent. Risk factors include prior history of high altitude illness, lack of acclimatization, heavy physical exertion, rapid rate of ascent, and abrupt ascent from lower altitudes.

2020年5月19日 星期二

Benzbromarone 促尿酸排泄 Gouless Euricon

促尿酸排泄藥物 (benzbromarone, sulfinpyrazone) 
對尿酸之製造無影響,而僅是增加其排除
會增加尿路結石及尿酸腎病變機率
因此不適用於下列病患:
(1) 製造過多引起的高尿酸血症
(2) 腎功能降低時,此類藥物會失去效用,尤其是 sulfinpyrazone 在肌酸酐廓清率 (creatinine clearance, CCr) <30 mL/min 時無效,宜避免使用
(3) 有尿酸成分尿路結石者為禁忌,因易增加尿路結石及尿酸腎病變危險。

促尿酸排泄藥物通常要從小劑量開始,且喝水要充足,以預防尿路尿酸結石的副作用。

Benzbromarone
初始劑量 50 mg qd. 需多喝水
Peak: 服藥之後 2-3 小時到達最大血中濃度
Duration: 半衰期 half life 12-13 小時
Max 100 mg qd. (但euricon原廠仿單說 150 mg qd)

警示, 六個月內應定期檢查肝功能.
1. 猛爆性肝炎, 服藥六個月內可能發生
2. 肝功能異常需停藥. 

禁忌
1. 腎結石病患, 嚴重腎功能不良
2. 懷孕或可能懷孕的婦女
3. 肝功能異常.

注意事項:
1. 急性痛風發作不要吃
2. 服藥初期有誘發痛風的可能
3. 尿液在酸性環境容易產生尿酸結石, 應增加喝水



2020年5月18日 星期一

Bell's palsy and Ramsay hunt syndrome 顏面神經麻痺 耳朵皰疹

下面這篇是黃醫師找到的, 來不及翻譯. 另外貼這裡 

Abstract

BACKGROUND:

Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. This review was first published in 2001 and most recently updated in 2015. Since a significant benefit of corticosteroids for the early management of Bell's palsy has been demonstrated, the main focus of this update, as in the previous version, was to determine the effect of adding antivirals to corticosteroid treatment. We undertook this update to integrate additional evidence and to better assess the robustness of findings, taking risk of bias fully into account.

AUTHORS' CONCLUSIONS:


The combination of antivirals and corticosteroids may have little or no effect on rates of incomplete recovery in comparison to corticosteroids alone in Bell's palsy of various degrees of severity, or in people with severe Bell's palsy, but the results were very imprecise. Corticosteroids alone were probably more effective than antivirals alone and antivirals plus corticosteroids were more effective than placebo or no treatment. There was no clear benefit from antivirals alone over placebo.The combination of antivirals and corticosteroids probably reduced the late sequelae of Bell's palsy compared with corticosteroids alone. Studies also showed fewer episodes of long-term sequelae in corticosteroid-treated participants than antiviral-treated participants.We found no clear difference in adverse events from the use of antivirals compared with either placebo or corticosteroids, but the evidence is too uncertain for us to draw conclusions.An adequately powered RCT in people with Bell's palsy that compares different antiviral agents may be indicated.下面這篇是黃醫師找到的, 來不及翻譯. 另外貼這裡 

Abstract

BACKGROUND:

Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. This review was first published in 2001 and most recently updated in 2015. Since a significant benefit of corticosteroids for the early management of Bell's palsy has been demonstrated, the main focus of this update, as in the previous version, was to determine the effect of adding antivirals to corticosteroid treatment. We undertook this update to integrate additional evidence and to better assess the robustness of findings, taking risk of bias fully into account.

AUTHORS' CONCLUSIONS:


The combination of antivirals and corticosteroids may have little or no effect on rates of incomplete recovery in comparison to corticosteroids alone in Bell's palsy of various degrees of severity, or in people with severe Bell's palsy, but the results were very imprecise. Corticosteroids alone were probably more effective than antivirals alone and antivirals plus corticosteroids were more effective than placebo or no treatment. There was no clear benefit from antivirals alone over placebo.The combination of antivirals and corticosteroids probably reduced the late sequelae of Bell's palsy compared with corticosteroids alone. Studies also showed fewer episodes of long-term sequelae in corticosteroid-treated participants than antiviral-treated participants.We found no clear difference in adverse events from the use of antivirals compared with either placebo or corticosteroids, but the evidence is too uncertain for us to draw conclusions.An adequately powered RCT in people with Bell's palsy that compares different antiviral agents may be indicated.

2020年5月15日 星期五

藥物不良反應 副作用 Statins

2014年 CLINICAL REVIEW  有一篇文章
Statin Adverse Effects: Sorting out the Evidence; Clinician Reviews. 2014 November;24(11):41-43,46-50

哪一種statin 比較安全呢?
WHICH DRUG? POTENTIAL DIFFERENCES IN STATINS

肝毒性機率並不高
HEPATIC EFFECTS ARE RARE

Historically, statins have been linked to potential hepatotoxicity, with case reports of serum transaminase elevation, cholestasis, hepatitis, and acute liver failure. It is now recognized that hepatic AEs are rare and that statins are not associated with a risk for acute or chronic liver failure.1,11 In patients with coronary heart disease, the incidence of hepatotoxicity with statin use is reported to be less than 1.5% over the course of five years and appears to be dosedependent.1 In 2012, the FDA revised the labeling for most statins, relaxing its earlier recommendations formonitoring of liver function, clarifying the risk for myopathy, and providing additional information about drug interactions.13 Checking transaminase levels before initiating therapy is recommended by both the ACC/AHA and the FDA.1,13 Routine monitoring is not necessary, the ACC/AHA guideline states, because RCTs have found little evidence of ALT/AST elevation.1 But here, too, evidence varies. An older meta-analysis (13 trials and nearly 50,000 participants) concluded that as a class, statins have no greater risk for transaminase elevations than placebo.22 But the 135-RCT meta-analysis4 found otherwise: Statins did increase the risk for transaminase elevation (odds ratio [OR], 1.51) compared with placebo, with differences associated with particular drugs and higher doses associated with more clinically significant elevations.4 It is important to note, however, that there was signifcant heterogeneity among the studies and no consistent definition of clinical significance. The bottom line: Statins have been shown in multiple prospective studies to be safe for patients with chronic liver disease.2

Statins 會造成DM 嗎? 機率並不高, 各種STATINS之間差異也不大. 有一篇分析 11 萬名病患的統合分析發現, 沒有統計上意義.
STATIN USE AND DIABETES: IS THERE A LINK?
Recent studies have found an increased risk for newonset type 2 diabetes in statin users, with a greater risk associated with higher-potency statins, including rosuvastatin and atorvastatin.4,24 Although the exact mechanism is not known, statins may modify insulin signaling in peripheral tissues or directly impair insulin secretion. The ACC/AHA guideline reports an excess rate of diabetes of one per 1,000 patient-years for moderateintensity therapy and three per 1,000 patient-years for high-intensity therapy.1 The 2013 meta-analysis found that the elevated risk for diabetes was relatively small (OR, 1.09).4 No difference among various statins was found. In another meta-analysis—this one encompassing 17 RCTs and more than 110,000 patients—no statistically significant difference in the incidence of new-onset diabetes was seen based on either the specific statin being taken or the intensity of therapy (high vs moderate)

一篇收集 24 萬人的統合分析發現
1. 所有statins, 因為副作用停藥的比例 5.7%
2. Atovastatin 和 Rosuvsatatin 停藥機率最高
3. Atovastatin 和 Fluvastatin 發生肝指數上升機率最高 (OR 各為 2.6 及 5.2 )
4. 患者對於 Pravastatin 和 Simvastatin 耐受性最佳, 這兩個是最安全的, 因副作用停藥機率最低
5. Simvastatin 如果服用超過一天40mg, 會顯著增加 CK 及 GPT(ALT) 上升機率 (OR 4.1 及 2.8), 罹患橫紋肌溶解機率也會上升

A meta-analysis with more than 240,000 participants evaluated patients taking seven different statins (atorvastatin, fluvastatin, lovastatin, pravastatin, pitavastatin, rosuvastatin, and simvastatin), looking at AEs of the drugs both collectively and individually.4 As noted earlier, the overall discontinuation rate due to AEs for all statins was 5.7%. Discontinuation rates for each agent were not reported.4

The researchers did report, however, that atorvastatin and rosuvastatin had the highest discontinuation rates; atorvastatin and fluvastatin had the highest incidence of transaminase elevations (OR, 2.6 and 5.2, respectively); and pravastatin and simvastatin appeared to be the best-tolerated and safest statins, with the lowest discontinuation rates. However, higher doses of simvastatin (> 40 mg/d) significantly increased the risk for CK and transaminase elevations (OR, 4.1 and 2.8, respectively),4 as well as the risk for rhabdomyolysis when taken at the highest dose.15,16

藥物不良反應 Statins pitavastatin

rate of adverse reactions/side effects
不良反應/副作用的機率
注意, 應該扣去安慰劑的比例
安慰劑造成肢體疼痛的機率比pitavastatin 2mg, 4mg 還高
對於pitavastatin 4 mg 而言, 背痛和肢體疼痛機率比安慰劑低, 便秘機率大於安慰劑, 肌肉痠痛機率高於安慰劑.

警示

WARNINGS & PRECAUTIONS
Myopathy and Rhabdomyolysis: Risk factors include age 65 and greater, renal impairment, inadequately treated hypothyroidism, concomitant use of certain drugs, and higher doses of ZYPITAMAG. ZYPITAMAG is contraindicated in patients taking cyclosporine and not recommended in patients taking gemfibrozil. The following drugs when used concomitantly with ZYPITAMAG may also increase the risk of myopathy and rhabdomyolysis: lipid-modifying dosages of niacin (>1 g/day), fibrates, and colchicine. Discontinue ZYPITAMAG if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue ZYPITAMAG in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis; e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the ZYPITAMAG dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever.
Immune-Mediated Necrotizing Myopathy (IMNM): There have been rare reports of IMNM, an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents.
Hepatic Dysfunction: Increases in serum transaminases can occur. Rare postmarketing reports of fatal and non-fatal hepatic failure have occurred. Consider liver enzyme testing before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue ZYPITAMAG.
Increases in HbA1c and Fasting Serum Glucose Levels: Increases of each have been reported with statins, including ZYPITAMAG. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.

ADVERSE REACTIONS: The most frequent adverse reactions (rate ≥ 2%) are myalgia, back pain, diarrhea, constipation and pain in extremity. This is not a complete list of all reported adverse events.

2020年5月13日 星期三

血糖異常應該多久再次檢測

無症狀成人的糖尿病篩檢建議 page 25

曾檢查為葡萄糖失耐、空腹血糖偏高、 或 HbA1C ≥5.7% 者,建議每年篩檢
其他情況, 通常是三年篩檢一次




2020年5月3日 星期日

甲狀腺亢進~停藥條件及停藥後的追蹤

甲狀腺功能異常-台大醫院衛教文章
甲狀腺機能異常與藥物治療
何時可考慮讓甲狀腺亢進病患停用藥物?
甲狀腺亢進停藥條件
治療一年之後(通常建議12-18個月)
.... 抗甲狀腺藥物治療時間通常是 1-2 年. 有研究說, 使用半年就停藥的復發機率較高
甲狀腺濃度正常.
沒有臨床症狀,
促甲狀腺分泌抗體 TSI 已經無法測得

抽血檢驗
停藥後至少追蹤甲狀腺功能3年 (第一年隔3~6個月,以後每隔6~12個月追蹤一次)
- 停藥第一年, 三個月抽血一次
- 停藥第二第三年, 6 個月抽血一次

如果 TSH 濃度上升, 應考慮再治療一年.

停用甲亢藥物之後, 應追蹤甲狀腺素三年
甲亢症復發通常是在停藥第一年內
第一年, 每三個月抽血一次
之後6個月抽血一次

甲亢症在停藥數年後仍可能發生
再發之後, 建議使用放射性碘, 或者手術治療, 也可以再次服用抗甲狀腺藥物

2020年5月2日 星期六

糖尿病合併慢性腎病/腎衰竭/腎功能不良/透析患者的藥物選擇

DPP4i
Onglyza (Saxagliptin) F.C Tab. 5mg CCR<30 2.5mg QD 但洗腎患者不建議使用
Trajenta (Linagliptin)不用調整劑量
Galvus (vildagliptin)eGFR < 50 劑量 50mg qd. 
Januvia 100 mg (sitagliptin) eGFR 45-60 不用調整劑量. 

Diabetes treatment in patients with renal disease: Is the landscape clear enough?

PRESCRIBING GUIDANCE IN PATIENTS WITH RENAL IMPAIRMENT TREND-UK: the diabetes nursing pioneers WWW.TREND-UK.ORG INFO@TREND-UK.ORG  @_TRENDUK TRAINING, RESEARCH AND EDUCATION FOR NURSES IN DIABETES Kindly provided through a PCDS and TREND-UK collaboration - July 2017

2016-09-30 藥學雜誌電子報

CKD stage 4-5 eGFR <30
第四及第五期慢性腎病, 不需調整劑量的抗糖尿病藥物
Pioglitazone 腎衰竭要小心使用 
Trajenta (Linagliptin)不用調整劑量


另一篇說 Gliclazide 和  clipizide 在腎衰竭是可以用的.
Gliclazide
Gliclazide is metabolized by the liver to inactive metabolites that are eliminated in the urine. Thus, gliclazide causes less hypoglycemia than other sulfonylureas. In CKD sage 1, 2, 3 (eGFR > 30 mL/min) gliclazide can be used. There are no data in patients with severe CKD but according to its metabolism the use (in reduced dose) of gliclazide is also permitted in these subjects[19].
Glipizide
Glipizide also does not need dose adjustment in severe and moderate renal disease and can be used safely. (The only caution remains the risk of hypoglycemia).

Pioglitazone: Glitis 30 mg. Actos 15 mg. TZD. 水腫.體液滯留 Cr>4 不用調整劑量
但洗腎患者不建議使用 TZD



Onglyza (Saxagliptin) F.C Tab. 5mg CCR<30 2.5mg QD 但洗腎患者不建議使用 
Trajenta (Linagliptin) 不用調整劑量 
Galvus (vildagliptin) eGFR < 50 劑量 50mg qd. 

CANAGLU 100MG Canagliflozin eGFR < 45 需停用 (Canaglu®可拿糖膜衣錠)

FORXIGA 10MG dapagliflozin eGFR< 45 需停用
 
JARDIANCE 25MG  empagliflozin eGFR<45 需停用
  








Pentoxiphylline 慢性腎病改善蛋白尿

Pentoxifylline 商品名 Ceretal, Pentop, Trental  循血敏 400mg

劑量 400mg TID. 腎功能不良需減量
eGFR 10-50 400mg BID
eGFR < 10 400mg QD
肝功能不良 400mg BID

Pentoxiphylline 應該服用多長時間療程仍不明. 

療效
1. 可改善蛋白尿
2. 是否能延緩 eGFR 衰退仍不明

methyl-xanthine 類衍生物
藉由非選擇性抑制 phosphodiesterase 而產生抗發炎與免疫調節等功能
可促進周邊血管灌流,常用於治療周邊血管或腦血管疾病

動物實驗
減少腎絲球 macrophage 產生
減少發炎前驅 cytokines, TNF-α, intercellular adhesion molecular 1 (ICAM-1)等物質的表現

藥物不良反應
 一般症狀包括噁心、嘔吐、腹瀉、頭痛、頭暈

藥物過量可能的症狀(需降低劑量). 
皮膚潮紅
心跳加快
胸悶
低血壓

禁忌
兒童、 視網膜出血、急性心肌梗塞、懷孕婦女
pentoxifylline 、 methylxanthines 、咖啡因、茶鹼等過敏者,不可使用。




膀胱過動症候群~頻尿、急尿、夜尿 Oxbu Betmiga

膀胱過動症, 不是單一疾病, 而是不同疾病總稱

症狀: 頻尿、急尿、夜尿
第一線治療: 行為治療
第二線治療: 藥物治療
第三線治療: 侵入性手術

第一線治療: 行為治療
排尿日誌,記錄三天, 瞭解病人的喝水量,排尿情形以及急尿感或漏尿的頻率。
每小時喝的水量,排尿時間及排尿量
急尿感或漏尿的情形
治療初步要讓病人了解排尿生理學,減少因為患者對於膀胱漲尿感覺太過敏感,導致習慣性排尿,再者要限制水分的過度攝取,避免容易刺激尿路上皮的食物或飲料,利用膀胱訓練來降低頻尿,急尿的感覺。

第二線治療: 藥物治療

藥物治療以抗膽鹼藥物為主,作用機轉~拮抗膀胱的乙醯膽鹼受體,減少膀胱逼尿 肌收縮。
禁忌: 隅角閉鎖性青光眼、胃排空延遲(gastric retention)、重症肌無力、尿液滯留

抗膽鹼藥物包含 darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine
1. 各類藥物特性不同
2. 各類藥物療效差異不大
3. 緩釋劑可減少副作用(口乾)



第二種藥物 mirabegron (Betmiga貝坦利持續性藥效錠25毫克)
選擇性 β3 乙型交感受體促進劑
作用機轉: 活化膀胱逼尿肌β3受體,進而抑制逼尿肌收縮,增加膀胱儲尿容積,
改善尿失禁症狀方面與抗膽鹼類藥物具相似療效,但價格較高。

mirabegron 劑量 25-50mg QD, 藥物半衰期長,一天一次即可

mirabegron 禁忌
血壓控制不良患者 (超過 180/110 mmHg)

藥物治療效果 (抗膽鹼/ mirabegron)
需服用 2-4 周才會達到明顯效果
若抗膽鹼藥物治療效果不佳, 可加上 mirabegron 
副作用太大, 調整劑量或更換另一種抗膽鹼藥物

副作用~口乾、便秘以及認知功能下降
1.機率與安慰劑相似
2.機率低於抗膽鹼藥物

其他副作用: 高血壓、鼻咽發炎(nasopharyngitis) 頭痛, 泌尿道感染

2020年5月1日 星期五

止痛藥與抽菸~何者發生慢性腎病機率高?

2015台灣慢性腎臟病臨床診療指引_國家衛生研究院
下載區

UKPDS 資料: 2006 年發表, 追蹤 5,102 名腎功能正常無白蛋白尿之 DM 成年人 15 年

1. 糖尿病
2003 年美國馬里蘭州研究, 追蹤20年
DM男性相較於沒有DM的男性, CKD 風險比 Hazard Ratio 5.0
DM女性相較於沒有DM的女性, CKD 風險比 Hazard Ratio 10.7
UKPDS 資料
DM 控制不良是未來發生 CKD 的危險因子:
糖化血色素每上升 1%,則未來發生微量白蛋白尿(microalbuminuria)的 HR 為 1.08(95% CI 為 1.03–1.12);發生巨量白蛋白尿(macroalbuminuria)的 HR 為 1.10 (95% CI 為 1.02–1.18)。
DM 合併視網膜病變未來發生微蛋白尿的 HR 為 1.25 (95% CI 為 1.05–1.49),發生 GFR ﹤ 60 ml/min/1.73m2 的 HR 為 1.255(95% CI 為 1.020–1.544)

2. 高血壓
UKPDS 資料發現高血壓是未來發生 CKD 的危險因子, 收縮壓每上升 10 mmHg
** 未來發生微量白蛋白尿的 HR 為 1.15(95% CI 為 1.11–1.20)
** 未來發生巨量白蛋白尿 的 HR 為 1.15(95% CI 為 1.07–1.24),
** 未來發生 GFR<60 ml/min/1.73m2 的 HR 為 1.107(95% CI 為 1.06–1.16),
** 未來肌酸酐倍增的 HR 則為 1.39(95% CI 為 1.23–1.57)。

3. 心臟血管疾病
UKPDS 資料發現心血管疾病是未來發生 CKD 的危險因子
未來發生微白蛋白尿的 HR 為 1.46(95% CI 為 1.23–1.73)
發生巨量白蛋白尿的 HR 為 1.58(95% CI 為 1.16–2.15)

2007 年追蹤 13,826 名成年人的世代研究發現,有中風、心絞痛、間歇性跛行、 短暫性中風、接受開心手術或心導管術等心血管疾病成年人,未來發生 CKD 或腎功 能惡化較速的風險均較高﹔
追蹤九年後,發生腎功能下降有 520 人(3.8%),而發生 CKD 有 314 人(2.3%)
預測因子包括病前的心血管疾病勝算比(Odds Ratio, OR)=1.70;95% CI 為 1.36-2.13。

4. 家族病史
因高血壓(OR=1.5;95% CI 為 1.1-2.1)、糖尿病(OR=1.9;95% CI 為 1.4-2.6),與腎絲球腎炎(OR=2.1;95% CI 為 1.5-3.0)所引起的 ESRD,其家族成員中會有較高的風險有ESRD。

5. 高血脂
TG高, CKD風險上升
HDL高, CKD風險下降
LDL 與CKD 無關

6. 服用草藥
累積61∼100克以上的木通, 發生 ESRD 的 OR 為 1.47(95% CI 為 1.01-2.14)
累積200 克木通發生 ESRD 的 OR 為 5.82(95% CI 為 3.89-8.7)

與未服用防己的病人比較
累積 61 ∼ 100 克以上的防己,發生 ESRD 的 OR 為 1.60(95% CI 為 1.20-2.14);
累積 200 克防己 發生 ESRD 的 OR 為 1.94(95% CI 為 1.29-2.92)
目前除了特定中草藥(如馬 兜鈴酸屬)之外,並無直接證據證實此相關性是否有因果關係
(雖有相關, 未必是因果關係)

7.急性腎損傷病史
心導管術後急性腎損傷, 未來需透析及死亡率 HR 1.91
外科手術, 術前腎功能正常, 術後發生急性腎損傷, 未來 ESRD 的 HR 22.69
術前有 CKD,術後發生 AKI , 未來發生 ESRD 的 HR 為 181.89
無 CKD、但發生 AKI 完全恢復者,未來發生 ESRD 的 HR 為 4.50(95% CI 為 2.43–8.35)

8. 老年人
( 八 ) 老年人
2003 年美國健康營養調查資料收錄 15,625 名非機構的 20 歲以上成年人CKD 盛行率為 11%,
腎絲球過濾率 eGFR < 60 ml/min/1.73m2 比率
** 20-39 歲族群 0.9%
** 40-59 歲佔 1.2%
** >70 歲族群佔 16%

UKPDS 資料發現年齡是未來發生 CKD 的危險因子, 年齡每增加五年
未來發生巨量白蛋白尿 HR 為 1.02(95%CI 為 0.94–1.12)
發生 GFR ﹤ 60 ml/ min/1.73m2 的 HR 為 2.15 (95% CI 為 1.98–2.34)
發生微量白蛋白尿風險則為不顯著升高,HR 為 1.01(95% CI 為 0.97–1.06)

9. 肥胖, 過重, 代謝症候群, 特徵~中央型肥胖、胰島素抗性、高三酸甘油脂血症
代謝症候群會增加 CKD機率

10. 長期吃止痛藥, 發生CKD風險增加 2.2 倍

11. 抽菸發生CKD風險, 男性增加 2.4 倍, 女性增加 2.9 倍
UKPDS 資料發現吸菸是未來發生 CKD 的危險因子
曾吸菸的成年人較未曾吸菸者相比,
發生微蛋白尿 HR 為 1.20(95% CI 為 1.01–1.42)
發生 GFR < 60 ml/ min/1.73m2 的 HR 為 1.25(95% CI 為 1.03–1.52)

12. 生活型態
中度活動量, 發生糖尿病腎病變/高血壓腎病變的 RR 3.7
低度活動量, 發生糖尿病腎病變/高血壓腎病變的 RR 10.1

13. 高尿酸血症或痛風
2013 年嘉義長庚醫院收錄 993 名無 CKD、無微蛋白尿病人發現,追蹤四年後, 新發生微蛋白尿的危險因子包括高尿酸血症
尿酸值每升高 1 mg/dL,則發生微蛋白 尿 OR 為 1.42(95% CI 為 1.27-1.59)

高血脂與慢性腎病 hyperlipidemia and CKD

2015台灣慢性腎臟病臨床診療指引

TG高, CKD風險上升
HDL高, CKD風險下降
LDL 與CKD 無關

高血脂 2000 年美國一項世代研究收錄 12,728 名腎功能相對良好的個案(男性血清肌酸 酐﹤ 2 mg/dL、女性﹤ 1.8 mg/dL),追蹤至血清肌酸酐上升 0.4 mg/dL 為觀察終點

2.9 年後發現,191 人達到試驗目標(5.1/ 千人年)
血中 TG 最高四分位病人相對最低四分位病人,發生 CKD 相對危險性(Rate Ratio, RR)為 1.65(95% CI 為 1.1-2.5)
HDL-C 最高的四分位受試者相較於最低的四分位者,未來發生 CKD 的 RR 是 0.47(95% CI 為 0.3-0.8)
LDL-C,並未與未來發生 CKD 相關

類固醇藥膏一次門診可以開幾條?

類固醇藥膏一次門診可以開幾條? 沒查到更詳細的描述
問皮膚科同學(同學的老公也是皮膚科), 她說她也不知道.
.
根據健保署108年藥品給付規定
13.3.2.含 calcipotriol 及類固醇之外用複方製劑(如 Daivobet)(94/5/1、99/12/1)
1.限確經診斷為尋常性牛皮癬(psoriasis)之病例使用,使用量以每星期不高於30gm 為原則,若因病情需要使用量需超過每星期30gm 者,應於病歷詳細紀錄理由。
2.同一部位之療程不得超過4週。

安眠藥物 Zaleplon zolpidem zopiclone eszopiclone 劑量 每天不要超過一顆

神經系統藥物 1.2.精神治療劑 Psychotherapeutic drugs
每天不要超過一顆. 需使用一顆以上. 可轉介精神科/神經科門診評估
連續使用不要超過六個月, 考慮會診精神科/神經內科
不建議併用兩種以上安眠藥.
第一次開安眠藥限七天

1.2.3. Zaleplon、zolpidem、zopiclone 及 eszopiclone(98/1/1、98/5/1、 98/10/1、102/11/1)

1.使用安眠藥物,病歷應詳載病人發生睡眠障礙的情形,並作適當的評估 和診斷,探討可能的原因,並提供衛教建立良好睡眠習慣。(98/5/1)

2.非精神科醫師、神經科專科醫師若需開立本類藥品,每日不宜超過一顆, 連續治療期間不宜超過 6 個月。若因病情需長期使用,病歷應載明原因, 必要時轉精神科、神經科專科醫師評估其繼續使用的適當性。(98/5/1、 98/10/1) 

3.精神科、神經科專科醫師應針對必須連續使用本藥的個案,提出合理的 診斷,並在病歷上詳細記錄。(98/5/1、98/10/1) 

4.依一般使用指引不建議各種安眠藥併用,應依睡眠障礙型態處方安眠 藥,若需不同半衰期之藥物併用應有明確之睡眠障礙型態描述紀錄,且應在合理劑量範圍內。(98/5/1)

5.對於首次就診尚未建立穩定醫病關係之病患,限處方 7 日內安眠藥管制

6. zaleplon 成分藥品用於治療難以入睡之失眠病人,僅適用於嚴重,病人 功能障礙或遭受極度壓力之失眠症患者,用於 65 歲以上病患時,起始劑 量為每日 5mg (98/1/1、98/10/1) 

7.成人病患使用 eszopiclone 成分藥品之起始劑量為睡前 1mg,最高劑量為 睡前 3mg,65 歲以上病患之最高劑量為 2mg。(102/11/1)

秒懂家醫科-血糖血脂(膽固醇)

2025-07-02 11:48AM 【門診醫學】 2024年美國糖尿病學會指引 【門診醫學】高膽固醇血症的治療建議 【預防醫學:什麼食物會升高膽固醇?】